Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs
  • M&A / Deals

LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs

Pharmaceutical Business Review

Executives from both organisations, including LG AI Research head Woohyung Lim and D D Pharmatech CEO Seulki Lee, attended the event to formalise the partnership.

Read full story

pharminent June 18, 2026 (Last updated: June 19, 2026)

Pharmaceutical Business Review

Executives from both organisations, including LG AI Research head Woohyung Lim and D D Pharmatech CEO Seulki Lee, attended the event to formalise the partnership.

Read full story

Post navigation

Previous: Biogen pens $1bn deal to buy immunology biotech RayThera
Next: GSK claims FDA okay for first oral carbapenem antibiotic

Related Stories

  • M&A / Deals

BioMarin spends up to $490m for Alesta’s bone disease candidate

pharminent August 19, 2026
  • M&A / Deals

J&J hands lymphoma bispecific CAR T back to AbelZeta

pharminent August 17, 2026
  • M&A / Deals

Novo Nordisk and AWS form AI partnership to speed drug discovery

pharminent August 17, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.